Skip to main content

Market Overview

52 Stocks Moving In Monday's Mid-Day Session



  • Arvinas, Inc. (NASDAQ: ARVN) shares jumped 103.4% to $60.87 after the company reported interim clinical data for its cancer treatment. The company said ARV-471 showed evidence of anti-tumor activity.
  • AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) gained 78.2% to $7.52 after the company said it made significant progress in detecting pre-cancer diseases.
  • Teligent, Inc. (NASDAQ: TLGT) jumped 64.8% to $1.0389 after declining over 8% on Friday. A Special Meeting of Stockholders is scheduled to reconvene on Wednesday December 16.
  • Veru Inc. (NASDAQ: VERU) shares climbed 60% to $10.17. Veru reported Phase 2 trial results for enobosarm for endocrine resistant metastatic breast cancer.
  • Rubius Therapeutics, Inc. (NASDAQ: RUBY) gained 45.9% to $9.32 after declining around 17% on Friday.
  • Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) shares jumped 30.4% to $157.71 after AstraZeneca plc (NASDAQ: AZN) announced plans buy the company for $39 billion.
  • Recro Pharma, Inc. (NASDAQ: REPH) gained 30.2% to $3.85 after climbing around 37% on Friday.
  • BioCardia, Inc. (NASDAQ: BCDA) shares rose 30.1% to $3.70. BioCardia said it expects data safety monitoring board verbal feedback for interim data from Phase 3 CardiaAMP heart failure trial by the end of December 15, 2020.
  • Evelo Biosciences, Inc. (NASDAQ: EVLO) surged 29.3% to $9.75 after jumping around 18% on Friday. Evelo Biosciences, last week, reported new clinical candidate in oncology.
  • Atomera Incorporated (NASDAQ: ATOM) surged 21.4% to $13.14.
  • Marathon Patent Group, Inc. (NASDAQ: MARA) shares gained 19.6% to $5.68 after declining 9% on Friday. HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $7.5 to $9. Marathon Patent Group last week purchased additional 10K S-19j Pro ASIC miners from Bitmain and announced plans to open a second data center.
  • DermTech, Inc. (NASDAQ: DMTK) shares surged 19.4% to $13.72. DermTech, on Friday, announced Inclusion of its melanoma test in two continuing medical education sessions at 2020 Fall Clinical Virtual Grand Rounds and Mount Sinai Winter Symposium.
  • Alimera Sciences, Inc. (NASDAQ: ALIM) gained 19% to $4.9747. Alimera Sciences, last week, reported the launch of ILUVIEN in The Netherlands.
  • 22nd Century Group, Inc. (NYSE: XXII) surged 18.8% to $3.02 after climbing 18% on Friday.
  • Homology Medicines, Inc. (NASDAQ: FIXX) rose 18.2% to $12.10.
  • Synlogic Inc (NASDAQ: SYBX) shares gained 17.4% to $2.63 after the company announced plans to advance its cancer treatment into the combination therapy stage of its phase 1 trial.
  • Gatos Silver, Inc. (NYSE: GATO) shares rose 16.6% to $8.77. Gatos Silver reported quarterly results last week.
  • Aligos Therapeutics, Inc. (NASDAQ: ALGS) gained 16.5% to $25.76.
  • ReneSola Ltd (NYSE: SOL) shares rose 16.4% to $6.45. HC Wainwright & Co. maintained ReneSola with a Buy and raised the price target from $4 to $12.
  • LogicBio Therapeutics, Inc. (NASDAQ: LOGC) surged 15.8% to $8.88.
  • Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) shares rose 15.4% to $11.71.
  • Inseego Corp. (NASDAQ: INSG) gained 15.4% to $15.87 after climbing 12% on Friday. The company on Thursday announced its 5G MiFi M2000 mobile hotspot is now available at T-Mobile and on Friday announced the availability of 5G MiFi M200 in Japan.
  • Chinook Therapeutics, Inc. (NASDAQ: KDNY) surged 14.9% to $15.31. Chinook Therapeutics reported a license agreement with Morehouse School of Medicine for development of therapies in kidney diseases disproportionately affecting African Americans and underserved communities.
  • Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) rose 14.7% to $54.88. Apellis and Sobi last week reported top-lone results at 48 weeks from Phase 3 PEGASUS study of pegcetacoplan in PNH.
  • Prevail Therapeutics Inc. (NASDAQ: PRVL) jumped 14.3% to $13.36. Prevail Therapeutics, last week, said first patient was dosed in Phase 1/2 PROCLAIM trial evaluating PR006 for the treatment of frontotemporal dementia patients with GRN mutations.
  • Nurix Therapeutics, Inc. (NASDAQ: NRIX) shares surged 14% to $45.30.
  • C4 Therapeutics, Inc. (NASDAQ: CCCC) gained 13.8% to $33.03.
  • Summit Wireless Technologies, Inc. (NASDAQ: WISA) surged 13.7% to $2.97 after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a $3.5 price target.
  • Socket Mobile, Inc. (NASDAQ: SCKT) climbed 13.6% to $3.0225 after the company announced it received a notice of forgiveness from Western Alliance Bank for the $1.06 million PPP loan.
  • GoHealth, Inc. (NASDAQ: GOCO) surged 12% to $14.88.
  • Riot Blockchain, Inc. (NASDAQ: RIOT) rose 10.6% to $9.58 after declining 7% on Friday.
  • Amarin Corporation plc (NASDAQ: AMRN) rose 6.2% to $5.32 after the company said VACEPA Covid-19 Cardiolink-9 randomized trial suggests improvement in outpatient-reported Covid-19 symptoms.
  • Pluralsight, Inc. (NASDAQ: PS) rose 6% to $20.10 after the company agreed to be acquired by private-equity firm Vista Equity Partners in an all-cash transaction for $20.26 per share..

Check out these big penny stock gainers and losers


  • Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO) shares dipped 46.9% to $1.1950 after the company disclosed results from its phase 2 trial of Razuprotafib glaucoma. HC Wainwright & Co. maintained Aerpio Pharmaceuticals with a Neutral and lowered the price target from $2 to $1.5.
  • Greenwich LifeSciences, Inc. (NASDAQ: GLSI) dropped 26.4% to $41.24 after declining over 22% on Friday. Greenwich LifeSciences last week shared the poster for the GP2 Phase 2b clinical trial final efficacy analysis that was presented Wednesday at the 2020 San Antonio Breast Cancer Symposium.
  • SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) fell 24% to $6.36. SELLAS Life Sciences Group shares tumbled around 53% on Friday after the company reported follow-up data from a randomized Phase 2 VADIS trial of Nelipepimut-S in woman with ductal carcinoma in-situ of the breast.
  • Destination XL Group, Inc. (NASDAQ: DXLG) fell 23.8% to $0.2397 after the company announced it would delist from the Nasdaq.
  • TechTarget, Inc. (NASDAQ: TTGT) dropped 16.8% to $50.08 after the company reported a proposed offering of convertible senior notes.
  • Gamida Cell Ltd (NASDAQ: GMDA) shares declined 15.8% to $8.36 after the company pushed back its timeline to submit a biologics license application from 2020 to 2H 2021 due to additional data requests from the Food and Drug Administration.
  • NextDecade Corporation (NASDAQ: NEXT) dipped 15.7% to $2.91 after climbing 38% on Friday.
  • SolarWinds Corporation (NYSE: SWI) fell 15% to $20.00 after the company said some of its products may have been affected by a highly sophisticated hack.
  • AMC Entertainment Holdings, Inc. (NYSE: AMC) dropped 14.8% to $3.34.
  • Fusion Fuel Green PLC (NASDAQ: HTOO) fell 14.6% to $16.82.
  • Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares fell 12.8% to $7.84. Vivos Therapeutics shares climbed around 50% on Friday after the company priced its IPO at $6 per share..
  • Immutep Limited (NASDAQ: IMMP) fell 12.7% to $3.0450 after declining over 38% on Friday. Immutep last week reported a statistically significant survival benefit for key patient groups in its ongoing Phase IIb AIPAC study in metastatic breast cancer.
  • Xenetic Biosciences, Inc. (NASDAQ: XBIO) fell 12.7% to $1.99. Xenetic Biosciences, last week, announced a roughly 2.45 million shares registered direct offering priced at $2.45 per share.
  • Fossil Group, Inc. (NASDAQ: FOSL) dropped 12.1% to $11.68.
  • Team, Inc. (NYSE: TISI) fell 11.6% to $9.82.
  • Virgin Galactic Holdings, Inc. (NASDAQ: SPCE) shares fell 11.1% to $28.47. A test flight of the VSS Unity from Virgin Galactic returned home early after an ignition failure on Saturday.
  • NantHealth, Inc. (NASDAQ: NH) dropped 10.5% to $3.08. NantHealth recently presented significant treatment insights at the 2020 San Antonio Breast Cancer Symposium in a time of need with the pandemic’s impact on cancer care.
  • Neos Therapeutics, Inc. (NASDAQ: NEOS) fell 8.2% to $0.6350. Neos Therapeutics and Aytu Biosciences last week announced a merger agreement.
  • AstraZeneca PLC (NYSE: AZN) fell 6.8% to $50.60 after the company announced it would acquire Alexion Pharmaceuticals for $39 billion in cash and stock.

Related Articles (ALIM + ALGS)

View Comments and Join the Discussion!

Posted-In: Mid-Day MoversNews Penny Stocks Small Cap Intraday Update Markets Movers Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at